Clinical trial Beamion LUNG-2
A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations (1479-0008 - Beamion LUNG-2 )
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Boehringer Ingelheim |
| EudraCT Identifier | 2023-504308-27-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06151574 |
| Last update |